BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 17692338)

  • 1. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptors-antagonists, molecular biology, and signal transduction.
    Jagadeesh G
    Indian J Exp Biol; 1998 Dec; 36(12):1171-94. PubMed ID: 10093499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new class of therapeutic agents: the angiotensin II receptor antagonists.
    Timmermans PB; Smith RD
    Cardiologia; 1994 Dec; 39(12 Suppl 1):397-400. PubMed ID: 7634303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
    Pichler M; Klein W; Huber K; Pachinger O
    Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].
    Burnier M; Brunner HR
    Therapie; 1998; 53(3):279-84. PubMed ID: 9773127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-peptide antagonists to angiotensin II receptors. A review].
    Schambye HT; Hjorth SA; Schwartz TW
    Ugeskr Laeger; 1993 Nov; 155(44):3558-62. PubMed ID: 8236577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y; Lefebvre J
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
    Brunner HR; Nussberger J; Waeber B
    J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.